John C. Reed, M.D., Ph.D. is president and chief executive officer of the Burnham Institute for Medical Research, one of the nation’s top biomedical research institutes. Dr. Reed leads several drug discovery efforts at the Burnham, including serving as director of the National Center for Chemical Library Screening based at Burnham and director of the Cancer Drug Discovery Group sponsored by the National Cancer Institute (NCI). Prior to being recruited to the Burnham in 1992, Dr. Reed was an assistant professor in the Department of Pathology & Laboratory Medicine at the University of Pennsylvania School of Medicine and assistant director of the Laboratory of Molecular Diagnosis at the Hospital of the University of Pennsylvania. Dr. Reed earned his M.D. and Ph.D. from the University of Pennsylvania School of Medicine, where he also received his clinical and postdoctoral training.
Dr. Reed’s research interests have focused primarily on cancer and he has been a pioneer in studying the mechanisms that regulate apoptosis, when cells commit suicide, and how defects in apoptosis contribute to diseases. Dr. Reed’s inventions have resulted in over 70 U.S. patents or patent applications, and have spawned numerous drug-discovery programs. He has been awarded over 80 research grants by a variety of funding agencies, including the National Institutes of Health (NIH), the American Cancer Society (ACS), and Susan G. Komen for the Cure. Dr. Reed is author of over 800 peer-reviewed scientific articles and over 50 book chapters, and he is the recipient of numerous awards for his research accomplishments.
Dr. Reed serves or has served on the editorial boards of numerous scientific journals and as an advisor to the NIH, the ACS, and the American Association for Cancer Research (AACR). He also serves or has served as an advisor and consultant to numerous biotechnology and pharmaceutical companies and on the board of directors of several public biopharmaceutical companies.
"I want to be involved with Breastcancer.org so I can continue to provide leadership in developing new therapies and diagnostic tests for women with breast cancer," Dr. Reed says.
Can we help guide you?
Create a profile for better recommendations
Tamoxifen (Brand Names: Nolvadex, Soltamox)
Tamoxifen is the oldest and most-prescribed selective estrogen receptor modulator (SERM)....
Breast Cancer Stages
The stage of a breast cancer is determined by the cancer’s characteristics, such as how large it...
Cancer Survivors Overestimate Quality of Their Diets
Most people who have been diagnosed with cancer think they eat a healthy diet, but a study found...